1. Scrip
  2. >>Business
  3. >>Earnings

Vertex Outlines Next Development Steps For Suzetrigine In Pain

 
• By Jessica Merrill

The company has accelerated a Phase II trial testing the NaV1.8 inhibitor in lumbosacral radiculopathy, and a Phase III trial in diabetic peripheral neuropathy will start this quarter.

Vertex updated investors on its diversification strategy • Source: Shutterstock

Vertex Pharmaceuticals Incorporated is already awaiting US Food and Drug Administration approval for its NaV1.8 inhibitor suzetrigine for the treatment of moderate-to-severe acute pain, but the company is advancing the drug into other late-stage clinical trials, with an eye toward expansion in peripheral neuropathic pain.

Key Takeaways
  • Vertex updated investors on Phase III development plans for the NaV1.8 inhibitor suzetrigine and povetacicept for IgA nephropathy (IgAN).

The company updated investors on the development of suzetrigine and other next-generation NaV1.8 and NaV1.7 inhibitors during its second quarter...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Earnings

Stock Watch: Generics Firms Trapped Between US Tariffs And European Austerity

 
• By Andy Smith

Successive annual reductions in European drug prices following the pandemic are affecting the global sales of generic pharmaceutical companies. Additionally, the imposition of US import tariffs may result in generic drug supply becoming unprofitable.

Stock Watch: On Q1 Vaccine Sales And Measles Outbreaks

 
• By Andy Smith

A recent study suggested that measles could become endemic in the US due to low vaccination rates. However, first-quarter vaccine sales offered a more nuanced picture.

Loss Of Exclusivity Product Launches To Fuel Aurobindo’s FY26 Europe Growth

 
• By Vibha Ravi

Aurobindo is banking on launches of loss of exclusivity products and biosimilars to fuel sales in Europe as it awaits a US announcement on tariffs and predicts high single-digit growth overall during FY26 for now

Korea Q1 Roundup: Mixed Earnings, Gearing For Possible US Tariffs

 
• By Jung Won Shin

South Korean biopharma companies report a mostly solid first quarter, marked by US growth for original drugs, with several also making preparations for possible US pharma tariffs.

More from Business

Sarepta Market Dynamics For Elevidys Imperiled By Second Patient Death

 
• By Joseph Haas

With two deaths in non-ambulatory DMD patients, Sarepta is attempting damage control and will ask the US FDA to advise, setting up a possible confrontation with CBER director Prasad.

Supernus Secures Sage With CVR-Supported Deal

 
• By Jessica Merrill

Supernus agreed to pay $561m upfront plus a contingent value right that could add $234m to buy Sage, topping a previously rejected offer from Biogen.

Early Blood Cancer Data Impresses As Incyte Plots Post-Jakafi Strategy

 
• By Kevin Grogan

First results for a first-in-class mutCALR-targeted therapy in essential thrombocythemia presented at EHA point to a lucrative future for the early-stage product.